Generic Name	Originator	Primary Therapy Description	Primary Pharmacology Description
aliskiren	Novartis	Antihypertensive, renin system	Renin inhibitor
ambrisentan	Abbott	Vasodilator, peripheral	Endothelin A receptor antagonist
arformoterol tartrate	Sepracor	COPD treatment	Long-acting beta 2 adrenoceptor agonist
clevudine	Bukwang	Antiviral, other	DNA directed DNA polymerase inhibitor
eculizumab	Alexion	Monoclonal antibody, humanized	Complement factor C5 inhibitor
epoetin delta	Shire	Recombinant growth factor	Erythropoietin agonist
garenoxacin	Toyama	Quinolone antibacterial	DNA topoisomerase ATP hydrolysing inhibitor
imidafenacin	Kyorin	Urological	Muscarinic M1 antagonist
ixabepilone	Bristol-Myers Squibb	Anticancer, other	Microtubule stimulant
HPV vaccine, GSK	GlaxoSmithKline	Recombinant vaccine	Immunostimulant
lapatinib ditosylate	GlaxoSmithKline	Anticancer, other	ErbB-2 tyrosine kinase inhibitor
maraviroc	Pfizer	Antiviral, anti-HIV	CC chemokine receptor 5 antagonist
nilotinib	Novartis	Anticancer, other	Bcr-Abl inhibitor
paliperidone	Johnson & Johnson	Neuroleptic	5-HT2 antagonist
Polyphenon E	Bradley Pharmaceuticals	Antiviral, other	Epidermal growth factor receptor antagonist
raltegravir	Merck & Co	Antiviral, anti-HIV	HIV integrase inhibitor
retapamulin	GlaxoSmithKline	Antibacterial, other	Protein synthesis antagonist
revaprazan	YuHan	Antiulcer	H+ K+ transporting ATPase inhibitor
Rexin-G	Epeius Biotechnologies	Gene therapy	Cyclin G1 inhibitor
Stiripentol	Biocodex	Antiepileptic	Sodium Channel antagonist
temsirolimus	Wyeth	Anticancer, antibiotic	mTOR kinase inhibitor
trabectedin	PharmaMar	Anticancer, alkylating	DNA antagonist
Tumour Necrosis Therapy	Peregrine Pharmaceuticals	Immunoconjugate, other	DNA antagonist
vildagliptin	Novartis	Antidiabetic	Dipeptidyl peptidase 4 inhibitor
vorinostat	Merck & Co	Anticancer, other	Histone deacetylase inhibitor
New active substances first launched in 2007 - © Informa UK Ltd